曲美他嗪对于冠心病合并左心功能不全的治疗价值分析

Treatment Value Analysis of Trimetazidine on Coronary Heart Disease With Left Ventricular Dysfunction

目的 探讨对冠心病合并左心功能不全(LVDD)患者予以曲美他嗪治疗的效果。方法 抽取2018年7月至2019年7月山东国欣颐养集团新泰汶南医院收治的66例冠心病合并左心功能不全患者参与研究,依照入院时间进行分组,各33例。对参照组使用基础用药治疗,实验组使用曲美他嗪治疗。计算心功能评级、心绞痛发作次数、收缩压、舒张压、实验室指标、依从性评分、满意度评分、生活质量评分。结果 实验组患者的心功能评级明显优于参照组,组间差异差异无统计学意义(P<0.05);实验组心绞痛发作次数低于参照组,两组差异明显(P<0.05);治疗前比较参照组,实验组收缩压、舒张压差异无统计学意义(P>0.05),治疗后与参照组数据相比较,实验组收缩压、舒张压较低,组间差异有统计学意义(P<0.05);比较治疗前实验室指标水平差异无统计学意义(P>0.05),相比于治疗后实验组数据,参照组实验室指标较高,差异有统计学意义(P<0.05)。与实验组数据相比较,参照组依从性评分、满意度评分、生活质量评分均较低,组间差异有统计学意义(P<0.05)。结论 对冠心病合并左心功能不全(LVDD)患者予以曲美他嗪治疗,使患者血管内皮功能和心功能得到明显改善,有利于心肌代谢,临床效果显著。

Objective To investigate effect of trimetazidine in treatment of coronary heart disease with left ventricular dysfunction (LVDD).Methods The paper chose 66 patients with coronary heart disease complicated with left ventricular dysfunction (LVDD) from July 2018 to July 2019 and divided them into two groups according to admission time,33 cases in each group.Control group was treated with basic medication,and experimental group with trimetazidine.Scores of heart function,angina attack times,systolic blood pressure,diastolic blood pressure,laboratory indexes,compliance score,and satisfaction degree and life quality were calculated.Results Cardiac function grading of experimental group was significantly better than control group,with significant difference between two groups,(P<0.05);frequency of angina attack in experimental group was lower than control group,with significant difference,(P<0.05).Before treatment,there was no significant difference in systolic and diastolic blood pressure between experimental group and reference group,(P>0.05).After treatment,systolic and diastolic blood pressure of experimental group was lower than reference group,with significant difference,(P<0.05).There was no significant difference in level of laboratory indexes before treatment (P>0.05).Data after treatment showed,laboratory indexes of reference group were higher,difference between two groups was significant (P<0.05).Compliance scores,satisfaction degree and life quality scores of reference group were lower than of experimental group,difference between two groups was significant (P<0.05).Conclusion Trimetazidine can improve vascular endothelial function and cardiac function of patients with coronary heart disease and left ventricular dysfunction (LVDD) significantly,which is conducive to myocardial metabolism and has significant clinical effect.